Core Insights - Clearmind Medicine Inc. has completed the enrollment of the last patient for the first cohort of its Phase I/IIa clinical trial for CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [6] Clinical Trial Details - The Phase I/IIa trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring preliminary efficacy signals such as reductions in alcohol cravings and consumption [3] - Six patients have been successfully enrolled in the trial, with two at Johns Hopkins University and four at Yale School of Medicine [2] - The trial is registered on ClinicalTrials.gov under the identifier NCT05913752 [4] Management Commentary - The CEO of Clearmind expressed enthusiasm about reaching a key milestone in the trial and highlighted the efficient enrollment process, which was completed within an excellent timeline [4]